TY  - JOUR
A1  - Himmelsbach, Vera
A1  - Pinter, Matthias
A1  - Scheiner, Bernhard
A1  - Venerito, Marino
A1  - Sinner, Friedrich
A1  - Zimpel, Carolin
A1  - Marquardt, Jens
A1  - Trojan, Jörg
A1  - Waidmann, Oliver
A1  - Finkelmeier, Fabian
T1  - Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers
T2  - Cancers
N2  - The combination of atezolizumab and bevacizumab (A + B) is the new standard of care for the systemic first-line treatment of hepatocellular carcinoma (HCC). However, up to now there are only few data on the safety and efficacy of A + B in real life. We included patients with advanced HCC treated with A + B as first-line therapy at four cancer centers in Germany and Austria between December 2018 and August 2021. Demographics, overall survival (OS), and adverse events were assessed until 15 September 2021. We included 66 patients. Most patients had compensated cirrhosis (n = 34; 52%), while Child–Pugh class B cirrhosis was observed in 23 patients (35%), and class C cirrhosis in 5 patients (8%). The best responses included a complete response (CR) in 7 patients (11%), a partial response (PR) in 12 patients (18%), stable disease (SD) in 22 patients (33%), and progressive disease in 11 patients (17%). The median progression-free (PFS) survival was 6.5 months, while the median overall survival (OS) was not reached in this cohort (6-month OS: 69%, 12-month OS: 60%, 18-month OS: 58%). Patients with viral hepatitis seemed to have a better prognosis than patients with HCC of non-viral etiology. The real-world PFS and OS were comparable to those of the pivotal IMBRAVE trial, despite including patients with worse liver function in this study. We conclude that A + B is also highly effective in a real-life setting, with manageable toxicity, especially in patients with compensated liver disease. In patients with compromised liver function (Child B and C), the treatment showed low efficacy and, therefore, it should be well considered before administration to these patients.
KW  - atezolizumab
KW  - bevacizumab
KW  - hepatocellular carcinoma
KW  - immunotherapy
KW  - real world
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/81935
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-819356
SN  - 2072-6694
VL  - 14
IS  - 7, art. 1722
SP  - 1
EP  - 12
PB  - MDPI
CY  - Basel
ER  -